"Investors anticipate FDA action to the persistent Ebola outbreak in Africa. The company has an RNAi therapeutic in development to treat Ebola infection. The FDA designated it Fast Track in March 2014.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.